Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388170 | 0.90 | CYP2D6 (0.56) | CYP2D6ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL14388258 | 0.85 | CYP2D6 (0.46) | CYP2D6ALDH1A1SMN1; SMN2KDM4EOPRM1 | |
| SCHEMBL8443208 | 0.83 | ALDH1A1 (0.47) | CYP2D6ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL8444064 | 0.81 | KDM4E (0.52) | CYP2D6ALDH1A1SMN1; SMN2KDM4EOPRM1 | |
| SCHEMBL8437435 | 0.81 | ALDH1A1 (0.55) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL12258804 | 0.80 | ALDH1A1 (0.51) | CYP2D6ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL8443686 | 0.79 | CNR1 (0.42) | CYP2D6ALDH1A1SMN1; SMN2KDM4EOPRM1 | |
| SCHEMBL8193648 | 0.78 | ALDH1A1 (0.50) | CYP2D6ALDH1A1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL12870586 | 0.78 | ALDH1A1 (0.50) | CYP2D6ALDH1A1KDM4EKMT2A | |
| SCHEMBL3934933 | 0.77 | CYP2D6 (1.00) | CYP2D6ALDH1A1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CYP2D6 1363/4885ALDH1A1 1683/4885SMN1; SMN2 3678/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CYP2D6 1363/4885ALDH1A1 1683/4885SMN1; SMN2 3678/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | CYP2D6 1404/4885ALDH1A1 1926/4885SMN1; SMN2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.